Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Zevalin (Ibritumomab Tiuxetan),ZevalinStudy001,2019,USA,MDV,350,62,45,55,27.5,32,85,5,15,35,30,20,60,25,10,5,25,40,35,12,5,3,7,4,10,40,30,CHOP,CVP,R-CHOP,Rituximab,0,0,0,15,50,60,20,50,30,40,2
Zevalin (Ibritumomab Tiuxetan),ZevalinStudy002,2020,Canada,Claim Database,420,68,48,52,28.1,35,82,6,12,38,32,18,58,27,9,6,22,42,36,14,6,4,8,5,12,42,32,CHOP,CVP,R-CHOP,Rituximab,0,0,0,17,52,62,18,52,30,42,3
Zevalin (Ibritumomab Tiuxetan),ZevalinStudy003,2021,UK,MDV,280,70,50,50,29.0,38,80,7,10,40,34,16,56,29,8,7,20,44,36,16,7,5,9,6,14,44,34,CHOP,CVP,R-CHOP,Rituximab,0,0,0,19,54,64,16,54,30,44,4
Zevalin (Ibritumomab Tiuxetan),ZevalinStudy004,2022,Germany,Claim Database,480,65,47,53,27.8,33,83,5.5,13,37,31,19,59,26,9.5,5.5,23,41,36,13,5.5,3.5,7.5,4.5,11,41,31,CHOP,CVP,R-CHOP,Rituximab,0,0,0,16,51,61,19,51,30,41,2.5
